newsfilter
← Latest News
GlobeNewswire·

BioCryst to Report Third Quarter 2026 Financial Results on November 4

  • BioCryst Pharmaceuticals will report Q3 2026 financial results on Wednesday, November 4, 2026.
  • Management will host a conference call & webcast at 8:30 a.m. ET to discuss results & provide a corporate update.
  • A live webcast & replay will be available in the investor section of www.biocryst.com.
  • BioCryst is a global biotechnology company focused on medicines for hereditary angioedema & other rare diseases.
  • The company has commercialized ORLADEYO®, the first oral, once-daily plasma kallikrein inhibitor.
  • BioCryst is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases.
  • Investor inquiries can be directed to investorrelations@biocryst.com.
  • Media inquiries can be directed to media@biocryst.com.